» Articles » PMID: 29744979

Knowledge of Naloxone and Take-home Naloxone Programs Among a Sample of People Who Inject Drugs in Australia: Variations Across Capital Cities

Overview
Specialty Psychiatry
Date 2018 May 11
PMID 29744979
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction And Aims: Take-home naloxone (THN) programs targeting people who inject drugs (PWID) have been running in some Australian states and territories since 2012. In this study, we aimed to determine the extent to which PWID in the capital cities of all Australian states and territories are aware of naloxone and THN programs, whether awareness of these programs has changed over time.

Design And Methods: Data were obtained from cross-sectional surveys of a total of 2088 PWID conducted annually as part of the Illicit Drug Reporting System from 2013 to 2015. Specific questions about THN added to the survey in 2013 allowed assessment of the extent to which sampled PWID were aware of naloxone and its function and THN programs in Australia and whether they had participated in a THN program. These main outcomes were examined over time and across states and territories using a mix of descriptive statistics and logistic regression.

Results: Over 80% of the sample reported having heard of naloxone across survey years. Less than half of the participants reported having heard of THN programs in 2013 (35%), but this increased to just over (52%) half in 2015 (P < 0.01). Changes over time differed across cities with increases in reports of having heard of THN occurring over time most clearly in those cities with operational THN programs.

Discussion And Conclusions: Around half of the PWID sampled for this study are aware of THN programs. Further work is needed to ensure widespread awareness of THN programs which should include implementing THN in all Australian states and territories.

Citing Articles

"Naloxone? Not for me!" First cross-assessment by patients and healthcare professionals of the risk of opioid overdose.

Aquizerate A, Rousselet M, Cochard A, Guerlais M, Gerardin M, Lefebvre E Harm Reduct J. 2024; 21(1):20.

PMID: 38263159 PMC: 10804588. DOI: 10.1186/s12954-024-00941-y.


"It can save your life, that's all I know," barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study.

Natale I, Harvey C, Wood P, Anderson K Qual Res Med Healthc. 2023; 7(2):10868.

PMID: 37692452 PMC: 10483482. DOI: 10.4081/qrmh.2023.10868.


Naloxone for opioid toxicity and overdose in the community.

Jauncey M, Nielsen S Aust Prescr. 2021; 44(2):38-39.

PMID: 33911329 PMC: 8075742. DOI: 10.18773/austprescr.2021.006.


Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment.

Gicquelais R, Mezuk B, Foxman B, Thomas L, Bohnert A Harm Reduct J. 2019; 16(1):46.

PMID: 31311572 PMC: 6636104. DOI: 10.1186/s12954-019-0317-3.